Additional legal action against McKinsey related to opioids by end of 2025?
Yes • 50%
No • 50%
Legal filings and announcements from the U.S. Department of Justice or other relevant authorities
FBI Boston: McKinsey to Pay $650 Million to Settle U.S. Opioid Probe Linked to Purdue Pharma on December 13, 2024
Dec 13, 2024, 02:18 PM
McKinsey & Company has agreed to pay $650 million to settle a U.S. Department of Justice investigation into its advisory role in promoting opioid sales, specifically for Purdue Pharma, the manufacturer of OxyContin. This settlement resolves both criminal and civil investigations into the consulting firm's actions, which have been linked to the opioid epidemic in the United States. The announcement was made during a news conference held by the FBI in Boston, where details about the resolution of these investigations were shared. Additionally, an ex-partner of McKinsey is expected to plead guilty to obstruction as part of the settlement.
View original story
Other • 25%
Securities and Exchange Commission • 25%
Federal Trade Commission • 25%
U.S. Department of Justice • 25%
Yes • 50%
No • 50%
Bain & Company • 25%
Boston Consulting Group • 25%
McKinsey & Company • 25%
Other • 25%
More than $2 billion • 25%
$1.5 billion to $2 billion • 25%
$1 billion to $1.5 billion • 25%
Less than $1 billion • 25%
Teva Pharmaceuticals • 25%
Johnson & Johnson • 25%
Other • 25%
Endo International • 25%
Reach new settlements with other firms • 25%
No significant actions • 25%
Rebrand or restructure • 25%
File for bankruptcy again • 25%
McKinsey & Company • 25%
Other • 25%
Accenture • 25%
Deloitte • 25%
More than $2 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%